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Background: Growing evidence suggests that microRNAs (miRNAs) play an important role in tumor development,
progression and metastasis. Aberrant miR-106b expression has been reported in several cancers. However, the role
and underlying mechanism of miR-106 in colorectal cancer (CRC) have not been addressed.
Methods: Quantitative RT-PCR(qRT-PCR) was performed to evaluate miR-106b levels in CRC cell lines and patient
specimens. Cell proliferation was detected using MTT assay, and cell migration and invasion ability were evaluated
by wound healing assay and transwell assay. The target gene of miR-106b was determined by qRT-PCR, western
blot and luciferase assays.
Results: miR-106b was significantly up-regulated in metastatic CRC tissues and cell lines, and high miR-106b expression
was associated with lymph node metastasis and advanced clinical stage. In addition, miR-106b overexpression
enhances, whereas miR-106b depletion reduces CRC cell migration and invasion. Moreover, we identify DLC1 as a
direct target of miR-106b, reveal its expression to be inversely correlated with miR-106b in CRC samples and show that
its re-introduction reverses miR-106b-induced CRC cell migration and invasion. Furthermore, survival analyses showed
the patients with high mi-106b/low DLC1 had shorter overall survival (OS) and disease-free survival (DFS) rates, and
confirmed miR-106b may be an independent prognostic factor for OS and DFS in CRC patients.
Conclusions: Our findings indicate that miR-106b promotes CRC cell migration and invasion by targeting DLC1. This
miRNA may serve as a potential prognostic biomarker and therapeutic target for CRC.
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Colorectal cancer (CRC) is one of the most common
malignant tumors worldwide and accounts for the fifth
leading cause of cancer death in China [1, 2]. Despite
achievements in the treatment in the few past decades,
CRC remains a major public health concern, resulting in
more than 600,000 deaths each year. The high mortality
rate of CRC is related mainly to frequent tumor recur-
rence and metastasis after surgical resection [3]. Thus,
there is an urgent need for the identification of meta-
static factors and understanding the molecular mecha-
nisms underlying CRC.* Correspondence: zhoutong0088@163.com
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creativecommons.org/publicdomain/zero/1.0/MicroRNAs (miRNAs) are small (approximately 22
nucleotides in length) non-coding RNAs that recognize
and bind to partially complementary sequences of their
target mRNA, resulting in either mRNA degradation or
inhibition of its translation [4]. MiRNAs regulate the
expression of a wide variety of target genes, and are
therefore involved in a wide range of biological pro-
cesses including cell proliferation, development and dif-
ferentiation [5–7]. Furthermore, increasing numbers of
miRNAs have been observed in various types of cancer
and may be involved in modulating cancer cell behav-
iors [8–13]. These data emphasize the importance of
miRNAs in cancer development and provide new in-
sights into understanding the molecular mechanism of
tumorigenesis and cancer metastasis.
Microarray studies have identified a number of micro-
RNAs that are up- or down-regulated in CRC, includingticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:73 Page 2 of 11miR-106b [14, 15]. To date, miR-106b has been found to
be deregulated in some types of cancers, such as in-
creased in bladder cancer [16], renal cell carcinoma [17],
laryngeal carcinoma [18] and hepatocellular carcinoma
[19], while decreased in endometrial cancer [20]. How-
ever, no specific studies have been conducted to reveal
the role of miR-106b in CRC.
Hence, our study was aimed to identify the role of
miR-106b in CRC. In present study, miR-106b expres-
sion was analyzed in CRC tissues and cell lines. After
that, we assessed the clinical significance of miR-106b in
colorectal cancer, and to investigate the effects of miR-
106b on CRC cell proliferation, migration and invasion
and further discuss the mechanisms of action of miR-
106b by identifying its potential target gene.
Materials and methods
Patients and tissue samples
Surgical specimens of cancer tissue and adjacent normal
mucosa (at least 5 cm from the margin of the tumor)
were obtained from 95 patients with colorectal cancer
who underwent surgery at The Affiliated Hospital of
North Sichuan Medical College between January 2006
and March 2009. Among the 95 patients, 2 patients di-
agnosed with distant metastases were excluded from our
study because these cases were too few for meaningful
statistical analysis. None of patients had received pre-
operative adjuvant therapy. After collection, all tissue
samples were immediately frozen in liquid nitrogen and
stored at −80 °C until use. Tumor stage was classified
according to the 7th edition of the UICC/AJCC TNM
staging system for CRC. Informed written consent was
obtained from each patient, and research protocols were
approved by the Medical Ethics Committee of North
Sichuan Medical College.
For follow-up, all patients were evaluated at the out-
patient clinic once per 3–6 month after discharge from
hospital. The median follow-up period was 61 months
(range, 11–81months). Follow-up studies included labora-
tory analysis, physical examination and computed tomog-
raphy if necessary. Patients who died from diseases other
than CRC or from unexpected events were excluded in
this study. Overall survival was defined as the time from
surgery to death, and disease-free survival as the time
from surgery to first tumor recurrence (local recurrence
and/or distal metastasis). Cases were censored at the date
of last follow up.
Cell culture
The human CRC cell lines (SW480, HCT116, HT29,
SW620 and LoVo), the human embryonic kidney cell line
293 T and the normal colon epithelium cell line FHC were
obtained from the American Type Culture Collection. The
CRC cell lines and 293 T cells were cultured in DMEM(Invitrogen, Carlsbad, CA, USA) supplemented with 10 %
fetal bovine serum (FBS; Invitrogen), and FHC cells were
grown in DMEM: F12 supplemented with 10 % FBS. All
cells were maintained in a humidified incubator at 37 °C
with 5 % CO2.
Oligonucleotides and plasmid transfection
MiR-106b mimics or inhibitor (anti-miR-106b) and their
negative controls (miR-nc mimics or anti-miR-nc) were
obtained from RiboBio (Guangzhou, China). The open
reading frame of DLC-1 that was amplified by PCR
using the primers containing KpnI and EcoRI restriction
sites and subcloned into vector pcDNA 3.1(+) (Invitrogen)
to generate the construct pcDNA-DLC1. The primers
used were 5’-CGAACGGTACCTGCTTGATGTGCAGA
AAGAAGCC-3’ forward and 5’-AAGGATCCTCACCTA
GATTTGGTGTCTTTG-3’ reverse. The empty vector
served as a negative control. Transfection was carried out
using Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s instructions.
RNA extraction and quantitative real-time PCR
Total RNA, including miRNA, was isolated from tissues
or cell lines using TRIzol reagent (Invitrogen) according
to manufacturer’s instructions. For miRNA expression
analysis, reverse transcription was performed using the
TaqMan microRNA reverse transcription kit (Applied
Biosystems, Foster City, CA, USA). Mature miR-106b
levels were quantified with TaqMan miRNA assays
(Applied Biosystems). For DLC1 mRNA detection, re-
verse transcription was performed using the PrimeScript
RT reagent Kit (Takara, Dalian, China). Quantitative PCR
was performed using SYBR Premix Ex Taq (Takara) on the
ABI 7500 real-time PCR System (Applied Biosystems). U6
snRNA or β-actin was used as internal control. The pri-
mer Sequences were as follows: DLC1, 5’-CCGCCTGAG
CATCTACGA-3’ forward and 5’-TTCTCCGA CCACTG
ATTGACTA-3’ reverse; β-actin, 5’-CCAAGGCCAACCG
CGAGAAGATGAC-3’ forward and 5’-AGGGTACATGG
TGGTGCCGCCAG AC-3’ reverse. The relative expres-
sion levels were calculated using the 2-ΔCT method, and
fold changes were calculated by the equation 2-ΔΔCT. For
the study of correlations between miR-106b and DLC1
expression, and correlations between miR-106b/DLC1
expression and survival in CRC patients, the miR-106b
and DLC1 expression levels were classified to low or high
group according to their respective median expression.
Cell proliferation analysis
Cell proliferation was measured using the MTT assay.
Briefly, the transfected cells were plated in 96-well plates
at 5 × 103 per well in a final volume of 100 μl, and 20 μl
of 5 mg/ml MTT was added to each well at 24, 48, 72
and 96 h. After incubation at 37 °C for 4 h, the MTT
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(DMSO) was added to each well followed by measuring
the absorbance at 570 nm on a SpectraMax M5 micro-
plate reader (Molecular Devices, Sunnyvale, CA, USA).
Wound healing and matrigel invasion assays
For the wound healing assay, cells (5 × 105) were seeded
into six-well plates and cultured under standard condi-
tions. When the cells reached confluence, a wound was
made by scraping the cell monolayer with a 200 μl pip-
ette tip. Cell migration was determined by measuring
the movement of cells into the scraped area. Representa-
tive images (20×) of wound closure were captured at 0 h
and 48 h using an inverted microscope. For the cell inva-
sion assay, cells (1 × 105) in serum-free medium were
placed into the upper chamber of a 24-well Transwell
Chamber (8 μm pore size, Corning Costar Corporation,
Cambridge, MA, USA) coated with Matrigel (BD Biosci-
ences, San Jose, CA, USA). The chambers were incu-
bated for 48 h with culture medium containing 10 %
FBS added to the lower chamber. The non-invaded cells
were removed with cotton swabs. Cells which had in-
vaded to the lower surface were fixed, stained and
counted using an inverted microscope (20×). All experi-
ments were performed in triplicate.
Luciferase reporter assay
For luciferase reporter experiments, the wild-type and
mutated 3’UTR of DLC1 mRNA were subcloned into the
XhoI and NotI site of the psicheck-2 vector (Promega,
Madison, WI, USA). and the new vectors were named
psicheck-2-DLC1-WT and psicheck-2-DLC1-MUT, re-
spectively. the following primers were used to amplify
specific fragments: DLC1-WT, forward 5’- CACAACT
CGAGGAATCCACCCA GAAAGGGGG-3’ and reverse
5’- CACAACACAAGCGGCCGCGTG G CTCAGTTG
CAGTTTGG-3’ and DLC1-MUT, forward 5’-AGCAAGTA
GTGAAATTCCCTGTTAGAATTCTTTGCATTTT-3’ and
reverse 5’- GG AATTTCACTACTTGCTTGATTTAAGA
GTAAGTGTTATC-3’. For the luciferase reporter assay,
HEK293T cells (1 × 105 cells/well) were cultured in a
24-well plate and co-transfected with 40nM miR-106b
mimics or inhibitor, 200 ng of psicheck-2-DLC1-WT or
psicheck-2-DLC1-MUT, and 2 ng of pRL-TK (Promega)
by using Lipofectamine 2000. The pRL-TK vector was
used as a normalisation control. After transfection for
48 h, cells were harvested and assayed with Dual- Lu-
ciferase Reporter Assay System (Promega) according to
the manufacturer’s protocols.
Western blot analysis
Cultured cells were lysed with RIPA lysis buffer contain-
ing proteinase inhibitor. Proteins were separated via
SDS-PAGE and transferred onto PVDF membrane. Afterblocking, the membrane was probed with mouse anti-
DLC1 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or mouse anti-GAPDH (1:1000; Santa Cruz) over-
night at 4 °C, followed by incubation with HRP-conjugated
secondary antibody (Santa Cruz). Signals were visualized
using ECL regents (Millipore, MA, USA).
Statistical analysis
For continuous variables, data are expressed as mean ±
standard deviation (SD). Statistical significance between
groups was analyzed by Student’s t-test, Mann–Whitney
U test or Kruskal-Wallis test, as appropriate. The post-
operative survival rate was analyzed with Kaplan–Meier
method and the survival differences of patient subgroups
were compared by the log-rank test. A Cox proportional
hazards model was used for multivariate analysis. The
correlation between miR-106b and DLC1 was deter-
mined by Chi-squared test and Spearman’s correlation
analysis. Statistical analyses were conducted using IBM
SPSS Statistics (Version 19, IBM SPSS, Chicago, IL,
USA). P < 0.05 was considered significant difference.
Results
MiR-106b is upregulated in metastatic CRC tissues and
cell lines
In this study, the levels of miR-106b were first measured
by quantitative real-time PCR (qRT-PCR) in 20 pairs of
normal tissues, primary CRC tissues and lymph node
metastatic tissues. As shown in Fig. 1a, miR-106b expres-
sion was significantly increased in primary CRC tissues
compared to their matched normal tissues. Furthermore,
in comparison to primary CRC tissues, miR-106b levels
were significantly higher in lymph node metastatic tissues
(P < 0.05, Fig. 1a). Consistent with these observations, the
expression of miR-106b was significantly up-regulated in
all five CRC cell lines compared with the normal colonic
cell line (Fig. 1b). Also, among the five CRC cell lines,
miR-106b levels were higher in metastatic CRC cells
(SW620 and LoVo) compared with non-metastatic ones
(HT29, HCT116 and SW480) (Fig. 1b). These findings
suggest that up-regulation of miR-106b might play a role
in CRC metastasis.
Correlation of miR-106b with clinicopathological factors
of colorectal cancer patients
To further investigate the clinicopathological signifi-
cance of miR-106b, we measured miR-106b expression
by qRT-PCR in a larger cohort of CRC tissues (n = 93).
As shown in Table 1, the miR-106b expression levels in
the tissues of CRC patients with lymph node metastasis
were significantly higher compared with those without
metastasis (P = 0.003, Fig. 2a). In addition, patients with
advanced stage(stage III) had higher miR-106b expression
than patients with early stage (stage I and II) (P = 0.008,
Fig. 1 The relative expression levels of miR-106b in CRC tissues and cell lines. a The relative expression of miR-106b in matched normal tissues,
primary CRC tissues and lymph node metastatic tissues. The expression of miR-106b was quantified by qRT-PCR and normalized to U6 snRNA;
P values were calculated using the paired t-test. b The relative expression of miR-106b in five CRC cell lines (HT29, HCT116, SW480, SW620 and
LoVo) and normal colonic cell line (FHC). *P < 0.05, **P < 0.01
Table 1 Association of miR-106b expression with clinicopathologic
factors of colorectal cancer patients
Variables n miR-106b expresion P
Gender 0.422
Male 54 4.619 ± 2.616
Female 39 5.102 ± 3.158
Age(years) 0.609
<60 43 4.657 ± 2.652
≥60 50 4.962 ± 3.028
Tumor Location 0.243
Colon 41 5.212 ± 3.176
Rectum 52 4.514 ± 2.553
Tumor size(cm) 0.341
≤5 59 4.607 ± 2.543
>5 34 5.194 ± 3.323
Tumor depth 0.106
T1-T2 27 4.053 ± 1.997
T3-t4 66 5.114 ± 3.115
Differentiation 0.516
Well 19 4.148 ± 2.055
Moderate 48 4.784 ± 2.851
Poor 26 5.388 ± 3.298
Lymph node metastasis 0.003
Absent 41 4.015 ± 1.940
Present 52 5.679 ± 3.096
TNM stage
I 9 3.219 ± 1.685 0.008
II 32 4.264 ± 1.957
III 52 5.679 ± 3.096
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between miR-106b expression and gender, age, tumor
location, tumor size, tumor depth and differentiation.
MiR-106b Promotes migration and invasion of CRC cells
To explore the potential biological function of miR-106b
in CRC progression, we transiently modulated the miR-
106b expression level by transfection with miR-106b
mimics or inhibitor. Re-expression or inhibition of miR-
106b was confirmed by qRT-PCR (Fig. 3a). Intriguingly,
the miR-106b expression had no effect on both types of
CRC cell proliferations (Fig. 3b). We then assessed the
effect of miR-106b on the migratory and invasive cap-
acity of CRC cells using the wound-healing assay and
matrigel invasion assay. As shown in Fig. 3c and D, miR-
106b overexpression significantly promoted the migra-
tion and invasion of SW480 cells. In contrast, miR-106b
knockdown suppressed LoVo cell migration and invasion.
These observations demonstrate that miR-106b signifi-
cantly promotes migration and invasion of CRC cells.
MiR-106b directly targets DLC-1 in CRC cells
To characterize the mechanism by which miR-106b pro-
motes cell migration and invasion, we searched for
potential target genes of miR-106b using three publicly
available databases, TargetScan, Pictar and miRanda. All
of the algorithms indicated that DLC1 was a theoretical
target of miR-106b(Fig. 4a).
DLC-1 was identified and selected for further analysis,
as it is a metastasis-suppressor gene which is down-
regulated in several tumor types [21]. To confirm whether
or not DLC-1 was a direct target of miR-106b, we inserted
wild-type or mutant 3’UTR sequences immediately down-
stream of the luciferase reporter gene and co-expressed
these with either miR-106b or anti-miR-106b in HEK293
Fig. 3 miR-106b promotes CRC cell migration and invasion. a The expression levels of miR-106b were tested by qRT-PCR in CRC cells transfected
with miR-106b, anti-miR-106b, and their respective negative controls. b The effect of miR-106b expression on cell proliferation was measured by
MTT assay. c The effect of miR-106b expression on migration of CRC cells using wound scratch healing assay. d The effect of miR-106b expression
on invasion of CRC cells using transwell invasion assay. *P < 0.05, **P < 0.01
Fig. 2 Upregulation of miR-106b is associated with advanced clinical stage and positive lymph node metastasis in CRC patients. a High expression
of miR-106b was associated with lymph node metastasis; patients were classified into lymph node metastasis negative group (LN-negative) and
positive group (LN-positive). bThe expression levels of miR-106b in different clinical stage of CRC patients. The expression of miR-106b was quantified
by qRT-PCR and normalized to U6 RNA. *P < 0.05, **P < 0.01, NS: non- significant
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Fig. 4 DLC1 is a direct target of miR-29c. a The wild-type and mutant of putative miR-106b target sequences of DLC1 3’UTR. (b,c) Analysis of the
luciferase activity of psicheck-2-DLC1 3’UTR WT and MUT vector in HEK293T cells by miR-106b or anti-miR-106b. d The DLC1 mRNA levels in the
indicated cells was analyzed by qRT-PCR. e The DLC1 protein levels in the indicated cells were examined by western blot. *P < 0.05, **P < 0.01
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caused a clear decrease in relative luciferase activity,
whereas miR-106b silencing increased the luciferaseactivity (Fig. 4c). In addition, mutation of the binding site of
miR-106b in the 3’UTR of DLC-1 abolished both the effect
of miR-106b and anti-miR-106b (Fig. 4b,c), confirming that
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qRT-PCR and western blotting analyses showed that
miR-106b overexpression significantly reduced the levels
of DLC1 mRNA and protein in SW480 cells, while miR-
106b knockdown increased DLC1 levels (Fig. 4d,e). To-
gether, these results strongly support a direct suppression
of DLC1 by miR-106b by means of mRNA degradation as
well as translational repression.DLC1 mediates miR-106b-induced migration and invasion
in CRC cells
To further confirm whether miR-106b promotes migration
and invasion of CRC cells through DLC1, we performed
a rescue experiment by introducing pcDNA3.1-DLC1
plasmid without 3’-UTR or empty vector in the presence
or absence of ectopic miR-106b expression in SW480
cells. After co-transfection, the expression of DLC1 was
confirmed by Western blotting as described in Fig. 5a.
In agreement with the expression of target proteins,
miR-106b mimics could augment the migratory and inva-
sive ability of SW480 cells, and the decreased metastatic
potential was also observed in DLC1-overexpressing cells
compared with control cells (Fig. 5b, c). Furthermore, con-
comitant overexpression of miR-106b and DLC1 could
partially abrogate miR-106b-induced migration and inva-
sion in SW480 cells (Fig. 5b, c). Thus, these findings show
that DLC1 is a functional target of miR-106b.Fig. 5 DLC1 mediates miR-106b-induced migration and invasion in SW480 ce
cells transfected with miR-106b mimic (miR-106b) and 3’UTR-negative DLC1 e
wound healing assay. c The invasive ability was examined by the matrigel invInverse correlation between miR-106b and DLC1 in CRC
tissues
To further investigate whether miR-106b-induced modula-
tion of DLC1 is of clinical relevance, we assessed the ex-
pression levels of DLC1 in clinical CRC tissues. As shown
in Fig. 6a, DLC1 levels were lower in CRC tissues with
lymph node metastasis compared with the lymph-node-
negative primary CRC tissues (P < 0.05). We then correlated
DLC1 with miR-106b expression in the same CRC
specimens. A statistically significant inverse correlation
was observed between mRNA levels of DLC1 and miR-
106b (P = 0.002, Fig. 6b). Furthermore, we found that
the high (or low) levels of miR-106b were more likely
to be observed in CRC tissues with low (or high) levels of
DLC1, providing more evidence for miR-106b mediated
DLC1 regulation (P = 0.017, Table 2).
Association of miR-106b and DLC1 expression with
overall and disease-free survival in CRC patients
Because miR-106b upregulation and DLC1 downregulation
were associated with CRC metastasis, we hypothesized that
miR-106b/DLC1 expression might be a prognostic factor
for survival in CRC patients. To validate this hypothesis,
the postoperative survival rates were analyzed using the
Kaplan–Meier method and log-rank test. The results
showed that patients with high miR-106b expression
had shorter overall survival (OS) and disease-free sur-
vival (DFS) than those with low miR-106b expressionlls. a The DLC1 protein levels were analyzed by Western blot in SW480
xpression plasmid (DLC1). b The migratory ability was detected by the
asion assay.*P < 0.05, **P < 0.01
Fig. 6 Inverse correlation between miR-106b and DLC1 in CRC tissues. a The expression of DLC1 in primary CRC tissues with or without lymph
node metastasis by qRT-PCR (n = 93). b Inverse correlation between miR-106b and DLC1 in CRC tissues determined by Spearman’s correlation
analysis (r = −0.314, P = 0.002). *P < 0.05
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We also observed that low DLC1 expression was associ-
ated with poor DFS (P = 0.033, Fig. 7d). however, low
DLC1 expression was not correlated with OS (P = 0.072,
Fig. 7c). In addition, the association between conjoined
expression status of miR-106b/DLC1 and the prognosis
of CRC patients was also tested. As expected, miR-
106b-high/DLC1-low patients had the poorest OS and
DFS in all four groups (Fig. 7e,f ). These data reveal that
miR-106b-DLC1 inverse regulation was associated with
a poor OS and DFS.
Furthermore, Cox multivariate analysis was performed
to identify independent prognostic markers for OS and
DFS. Since TNM stage is determined by tumor depth
and lymph node metastasis, it was not further enrolled
into the multivariate analysis in this study. The results
confirmed that miR-106b expression and lymph node
metastasis were independent prognostic factors for OS
and DFS, indicating that miR-106b could be used as bio-
markers of early recurrence and poor prognosis of CRC
(Table 3).
Discussion
The diagnosis and treatment of colorectal cancer (CRC)
have evolved substantially during the past decade with
the advent of molecular markers [22]. Recent evidence
has indicated that specific miRNAs have important
roles in carcinogenesis and metastasis [23], and theTable 2 Correlation between the expression of miR-106b and DLC-1
miR-106b
low high
(n = 46) (n = 47)
DLC-1
Low (n = 46) 17 29
High (n = 47) 29 18identification of tumor-related miRNAs and their direct
target genes is critical for understanding the biological sig-
nificance of miRNAs in CRC development and metastasis,
and may reveal novel prognostic and therapeutic targets
for CRC patients.
Previous reports revealed that miR-106b expression
was high in CRC by miRNA microarray analysis [14, 15].
In the current study, we further confirmed that miR-
106b was significantly up-regulated in metastatic CRC
tissues, and high miR-106b expression was associated
with lymph node metastasis and advanced clinical stage.
These results indicate that miR-106b may play an im-
portant role in the development and progression of
CRC, especially in the processes of metastasis. Several
studies support our results. For example, miR-106b pro-
motes cell migration and metastasis in hepatocellular
carcinoma [24]. MiR-106b is also found to promote gas-
tric cancer cell migration and invasion by targeting
PTEN [25]. However, miR-106b has been reported to
exert a metastasis-suppressor function in endometrial
cancer and breast cancer [20, 26]. The discrepancies in
miR-106b’s functions in different types of cancer may re-
flect the differences of cellular context or alternatively
the targeted genes.
It has been shown that high expression of miR-106b
associated with aggressive tumor phenotypes in this re-
port. However, the biological functions of miR-106b in
CRC are still unclear and need to be further elucidated.in 93 CRC patients
n P Spearman’ correlation
P r
93 0.017 0.017 −0.247
Fig. 7 Kaplan-Meier survival curves for CRC patients. (a,b) The OS and DFS curves for CRC patients with high or low miR-106b expression.
(c,d) The OS and DFS curves for CRC patients with high or low DLC1 expression. (e,f) The OS and DFS curves for CRC patients with concomitant
miR-106b and DLC1 expression
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expression was significantly increased in CRC cell lines
compared with the normal colonic cell line, and CRC cell
lines with metastasis capacity expressed higher miR-106b
than those without metastasis. These data led us to ask
whether miR-106b could regulate CRC metastasis or not.
Then, we further performed gain-of-function assays in
SW480 cell line (low-miR-106b) and loss-of-function
assays in LoVo cell line (high-miR-106b), and found
that up-regulation of miR-106b promotes migration and
invasion of SW480 cells, while down-regulation of miR-
106b inhibits migration and invasion of LoVo cellsTable 3 Multivariate COX proportional hazards regression model anal
Variables OS
HR 95 % CI
Gender 0.481 0.156-1.482
Age(years) 0.740 0.295-1.852
Tumor Location 0.482 0.133-0.749
Tumor size(cm) 0.476 0.184-1.230
Tumor depth 0.741 0.301-1.824
Differentiation 0.687 0.271-1.740
Lymph node metastasis 6.180 1.629-23.441
MiR-106b expression 3.946 1.052-14.804
DLC1 expression 0.603 0.219-1.657without affecting cell proliferation. These results indicate
that miR-106b is a metastatic promoter in CRC.
To explore the mechanisms underlying the promotion
of CRC cell migration and invasion mediated by miR-
106b, we next set out to identify the potential target
genes of miR-106b. In a number of cancers, miRNAs
regulate cell proliferation and metastasis by targeting de-
leted in liver cancer-1 (DLC1) [27, 28]. DLC1, a member
of RhoGTPase activating protein (GAP) family, has been
frequently under-expressed in a wide variety of human
tumors including CRC [29–31]. DLC1 is also known to
have suppressive activities in tumorigenicity and cancerysis for overall survival and disease-free survival in CRC patients
DFS
P HR 95 % CI P
0.202 0.701 0.285-1.723 0.438
0.520 0.846 0.384-1.863 0.678
0.267 0.891 0.388-2.046 0.786
0.125 0.805 0.327-1.977 0.636
0.514 0.625 0.277-1.414 0.259
0.428 0.632 0.253-1.580 0.326
0.007 3.813 1.340-10.852 0.012
0.042 3.472 1.134-10.631 0.029
0.326 0.445 1.177-1.117 0.085
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toration of DLC1 gene inhibits proliferation and migra-
tion of human colon cells [34]. It is well known that
Focal adhesion kinase (FAK) mediates several biological
functions including tumor cell proliferation, migration
and invasion [35]. FAK is highly expressed in CRC me-
tastases and is activated by its phosphorylation sites
thereby interacting with other signals to promote cell
migration [36, 37]. A recent report has suggested that
DLC1 binds to FAK and is important for its tumor sup-
pressive function [38]. The majority of sporadic forms of
colorectal cancer are characterized by deregulation of
Wnt/β-catenin signaling resulting in increased transcrip-
tional activity of the protein β-catenin [39]. It was re-
ported that DLC1 inhibited the growth and invasion of
colon cancer cells through the Wnt/β-catenin signaling
pathway by upregulating GSK-3β, and downregulating
β-catenin [40].
In this report, we identified DLC1 as a novel, direct
target of miR-106b using luciferase reporter assays. This
observation was confirmed by the fact that miR-106b
overexpression diminished but miR-106b knockdown in-
creased DLC1 mRNA and protein expression in CRC
cells. Moreover, we observed that the expression of miR-
106b correlated inversely with the expression of DLC1
in human CRC tissues, and ectopic expression of DLC1
significantly attenuated miR-106b induced cell migration
and invasion. These results demonstrate for the first
time that miR-106b can promote CRC migration and in-
vasion by directly targeting its target gene DLC1.
A recent study reported that low DLC1 by itself did
not have prognosis value in colon cancer patients, but
there is a prognostic significance when low DLC1 was
combined with low p15 or high Cdk6 in colon cancer
patients [29–31]. In line with these findings, we found
that low DLC1 expression was not associated with OS in
CRC patients. However, we determined low DLC1 ex-
pression was associated with worse DFS. Moreover, miR-
106b-high/DLC1-low status was significantly associated
with a shorter OS and a shorter DFS. Cox multivariate
analysis suggested that miR-106b represented an inde-
pendent prognostic factor for both OS and DFS. On the
basis of these findings, we suggest that a combined ana-
lysis of miR-106b and DLC1 expression status may en-
hance our accuracy in identifying patients at high risk of
poor prognosis, and hence provide useful information
for clinical management. The miR-106b expression may
be useful as a prognostic marker for the prediction of
survival and relapse in CRC patients.
In conclusion, this study demonstrates that miR-106b
can significantly promote CRC cell migration and inva-
sion by directly targeting DLC1, and revealed that high
miR-106b expression could serve as an independent pre-
dictor of poor prognosis and recurrence in CRC patients.The newly identified miR-106b/DLC1 axis helps to further
elucidate the complex molecular mechanisms which regu-
late metastasis and progression in CRC, and represents a
novel strategy for prognostic prediction and the treatment
of patients with CRC.
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